AU2001275191A1 - Method for the purification of alphavirus replicon particles - Google Patents

Method for the purification of alphavirus replicon particles

Info

Publication number
AU2001275191A1
AU2001275191A1 AU2001275191A AU7519101A AU2001275191A1 AU 2001275191 A1 AU2001275191 A1 AU 2001275191A1 AU 2001275191 A AU2001275191 A AU 2001275191A AU 7519101 A AU7519101 A AU 7519101A AU 2001275191 A1 AU2001275191 A1 AU 2001275191A1
Authority
AU
Australia
Prior art keywords
purification
alphavirus replicon
methods
replicon particles
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275191A
Inventor
Maria Calderon-Cacia
Daniel Del La Vega Jr.
Thomas W. Dubensky Jr.
Catherine Greer
John M Polo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2001275191A1 publication Critical patent/AU2001275191A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Powder Metallurgy (AREA)
  • Disintegrating Or Milling (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. In one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics
AU2001275191A 2000-05-31 2001-05-31 Method for the purification of alphavirus replicon particles Abandoned AU2001275191A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20837600P 2000-05-31 2000-05-31
US60208376 2000-05-31
PCT/US2001/018021 WO2001092552A2 (en) 2000-05-31 2001-05-31 Method for the purification of alphavirus replicon particles

Publications (1)

Publication Number Publication Date
AU2001275191A1 true AU2001275191A1 (en) 2001-12-11

Family

ID=22774372

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275191A Abandoned AU2001275191A1 (en) 2000-05-31 2001-05-31 Method for the purification of alphavirus replicon particles

Country Status (9)

Country Link
US (4) US6767699B2 (en)
EP (1) EP1285080B1 (en)
AT (1) ATE409749T1 (en)
AU (1) AU2001275191A1 (en)
CA (1) CA2410948C (en)
DE (1) DE60135983D1 (en)
DK (1) DK1285080T3 (en)
ES (1) ES2312447T3 (en)
WO (1) WO2001092552A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
CA2448066A1 (en) 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
AU2002327614B2 (en) * 2001-09-06 2007-12-06 Alphavax, Inc. Alphavirus replicon vector systems
US7195905B2 (en) * 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
ES2323454T5 (en) 2002-04-30 2012-11-14 Oncolytics Biotech Inc. Improved virus purification procedure
CA2500661A1 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same
EP1585812B1 (en) * 2002-12-13 2017-01-18 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
US7078218B2 (en) 2002-12-13 2006-07-18 Alphavax, Inc. Alphavirus particles and methods for preparation
KR101518309B1 (en) * 2003-03-20 2015-05-08 알파벡스, 인크. Improved alphavirus replicons and helper constructs
ES2327643T3 (en) * 2003-07-11 2009-11-02 Alphavax, Inc. VACCINES AGAINST CITOMEGALOVIRUS BASED ON ALFAVIRUS.
WO2005113782A1 (en) 2004-05-18 2005-12-01 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
EP2848692B1 (en) 2004-05-21 2017-08-16 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
EP1736538A1 (en) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
KR100760525B1 (en) * 2006-04-13 2007-10-04 김재만 Kit and method for quantitatively detecting multiple pathogens without gene amplification
US8263092B1 (en) 2006-09-12 2012-09-11 Alphavax, Inc. Alphavirus replicon particles as immunological adjuvants
EP2061508B1 (en) 2006-09-12 2014-10-15 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
NZ576563A (en) * 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
CA2689588C (en) 2007-06-21 2016-08-23 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
ES2525707T3 (en) 2008-12-01 2014-12-29 Alphavax, Inc. Use of microRNAs for the control of virus-collaborating nucleic acids
WO2010078556A1 (en) 2009-01-05 2010-07-08 Epitogenesis Inc. Adjuvant compositions and methods of use
US10072307B1 (en) 2009-01-23 2018-09-11 Colorado State University Research Foundation Isolation of viruses using anionic resin beads
WO2010118252A1 (en) 2009-04-08 2010-10-14 Alphavax, Inc. Alphavirus replicon particles expressing trp2
US9029517B2 (en) 2010-07-30 2015-05-12 Emd Millipore Corporation Chromatography media and method
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US10561720B2 (en) 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2016036508A1 (en) 2014-09-02 2016-03-10 Emd Millipore Corporation High surface area fiber media with nano-fibrillated surface features
JP6830059B2 (en) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド Scheduled cell feeding
KR102162753B1 (en) 2014-12-08 2020-10-07 이엠디 밀리포어 코포레이션 Mixed bed ion exchange adsorber
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10660950B2 (en) 2015-12-23 2020-05-26 Valneva Se Virus purification
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
CN117247899A (en) 2017-03-31 2023-12-19 泰尔茂比司特公司 cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
BR112020003470B1 (en) 2017-09-21 2023-09-26 Valneva Se PHARMACEUTICAL COMPOSITIONS COMPRISING THE IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NSP3, PROCESS AND USE THEREOF
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
WO2024149832A1 (en) 2023-01-12 2024-07-18 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466788A (en) * 1985-03-07 1995-11-14 Mycogen Plant Science, Inc. Subgenomic promoter
ES8800988A1 (en) 1985-04-05 1987-12-16 Meloy Lab Sustained high-level production of recombinant human gamma interferon using a bovine papillomavirus vector.
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
AU7780687A (en) 1986-07-23 1988-02-10 Aphton Corp. Immunogens and improved methods of making immunogens
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5093239A (en) 1988-05-02 1992-03-03 Eastman Kodak Company Reagents for detecting oxidase positive microorganisms
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5026686A (en) 1989-02-01 1991-06-25 Washington University Antiviral peptides
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
CA2066053C (en) 1989-08-18 2001-12-11 Harry E. Gruber Recombinant retroviruses delivering vector constructs to target cells
EP0554376A4 (en) 1990-10-22 1994-08-24 Fox Chase Cancer Center Dna construct for providing rna therapy
SE9003978D0 (en) 1990-12-13 1990-12-13 Henrik Garoff DNA EXPRESSION SYSTEM BASED ON A VIRUS REPLICATION
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
AU6172194A (en) 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
DE4315109A1 (en) 1993-05-06 1994-11-10 Inst Pflanzengenetik & Kultur Method and vector construct for increasing expression of transgenes
EP0647716B1 (en) 1993-07-06 2003-09-24 Universite De Nice-Sophia Antipolis Vector comprising viral gene transcribed by ARN polymerase III
US5837503A (en) 1993-07-07 1998-11-17 Universite De Nice-Sophia-Antipolis Vector containing viral gene transcribed by RNA polymerase III and methods for use
ES2328424T3 (en) * 1993-09-15 2009-11-12 Novartis Vaccines And Diagnostics, Inc. RECOMBINANT ALFAVIRUS VECTORS.
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5591579A (en) 1993-12-21 1997-01-07 Washington University Indicator cell line for detecting RNA viruses and method therefor
IL112371A0 (en) 1994-01-25 1995-03-30 Res Dev Foundation A novel protein from aedes albopictus cells and methods for its use
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
US5532154A (en) 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
GB9406498D0 (en) 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds
SE9401091D0 (en) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (en) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
JPH11511326A (en) * 1995-08-30 1999-10-05 ジエンザイム コーポレイション Purification of adenovirus and AAV
WO1997016169A1 (en) 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
WO1997030155A1 (en) 1996-02-15 1997-08-21 Chiron Corporation Gene therapy method using fgf-5
ES2301178T3 (en) 1996-04-05 2008-06-16 Novartis Vaccines & Diagnostic RECOMBINANT ALFAVIRUS-BASED VECTORS WITH REDUCED INHIBITION OF CELLULAR MACROMOLECULAR SYNTHESIS.
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6110898A (en) 1996-05-24 2000-08-29 University Of Maryland, Baltimore DNA vaccines for eliciting a mucosal immune response
US5843712A (en) 1996-06-06 1998-12-01 The Trustees Of Columbia University In The City Of New York Sindbis virus expression system for recombinant antibody production
WO1998013511A1 (en) 1996-09-25 1998-04-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic togavirus vectors
JP2001501483A (en) 1996-10-10 2001-02-06 ガロフ，ヘンリク Alphavirus-retrovirus vector
WO1998026084A1 (en) 1996-12-09 1998-06-18 Wolfgang Andreas Renner Expression of active interferon beta 1 using recombinant rna replicons
US6261823B1 (en) * 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6261570B1 (en) 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
EP0996737A1 (en) 1997-08-15 2000-05-03 Inex Pharmaceuticals Corp. Semliki forest virus vectors for gene transfer into non-endothelial cardiovascular cells
US6060308A (en) 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
CA2304983A1 (en) 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
US6475780B1 (en) 1997-11-14 2002-11-05 Aventis Pasteur Limited Alphavirus vectors for paramyxovirus vaccines
WO1999025859A1 (en) 1997-11-14 1999-05-27 Connaught Laboratories Limited Alphavirus vectors
WO1999030734A1 (en) 1997-12-18 1999-06-24 G.D. Searle & Co. Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity

Also Published As

Publication number Publication date
EP1285080A2 (en) 2003-02-26
WO2001092552A3 (en) 2002-05-23
ATE409749T1 (en) 2008-10-15
DK1285080T3 (en) 2008-12-01
CA2410948C (en) 2012-07-17
ES2312447T3 (en) 2009-03-01
US20050112752A1 (en) 2005-05-26
US20020015945A1 (en) 2002-02-07
CA2410948A1 (en) 2001-12-06
EP1285080B1 (en) 2008-10-01
US20100055128A1 (en) 2010-03-04
WO2001092552A2 (en) 2001-12-06
US20120231526A1 (en) 2012-09-13
DE60135983D1 (en) 2008-11-13
US6767699B2 (en) 2004-07-27

Similar Documents

Publication Publication Date Title
AU2001275191A1 (en) Method for the purification of alphavirus replicon particles
EP1399183A4 (en) Chimeric alphavirus replicon particles
HU9603155D0 (en) Papillomavirus vaccines
ZA200610561B (en) TC-83-derived alphavirus vectors, particles and methods
PT1651666E (en) Alphavirus-based cytomegalovirus vaccines
WO2005025536A3 (en) Dry powder composition comprising co-jet milled particles for pulmonary inhalation
IL153705A0 (en) Method of making particles for use in a pharmaceutical composition
DE60129695D1 (en) INCREASING IMMUNE RESPONSES MEDIATED BY ANTIBODY CYTOKIN FUSION PROTEINS BY COMBINED TREATMENT WITH MEDICAMENTS FOR INCREASING IMMUNOCYTIC INJECTION
WO2004087896A3 (en) Hepatocyte differentiation of stem cells
AU2002310321A1 (en) Compositions and methods for high-level, large-scale production of recombinant proteins
IL172634A0 (en) Agent for inhibiting membrane virus reproduction, method for the production thereof pharmaceutical composition and method for inhibiting viral infections
MX2022014161A (en) Sars-cov-2 vaccines.
WO2006041897A3 (en) Chimeric vectors
WO2004050680A3 (en) Use of spliceosome mediated rna trans-splicing to confer cell selective replication to adenoviruses
AU2001259217A1 (en) Human pellino polypeptides
AU2002216968A1 (en) Plasma fraction containing bikunin, method for the production thereof and use of the same
WO2008027560A3 (en) Holin-enhanced vaccines and reagents, and methods of use thereof
DK1423525T3 (en) Recombinant MVA capable of expressing HCV structural antigens
AU2003258611A1 (en) Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines
EP1015560A4 (en) Modified small rna viruses
FI20020375A (en) Method for generating virus-like particles (VKP), plasmid construct and uses of the method
WO2004056979A3 (en) Recombinant virus production for the manufacturing of vaccines
AU2001278139A1 (en) Enhanced replication of hcv rna
AU2003234712A1 (en) Differentially expressed genes involved in angiogenesis, the proteins encoded thereby, and methods of using the same
Baronova et al. Ion distribution according to ionization degrees in pinch plasma; Raspredelenie ionov po stepenyam ionizatsii v plazme pincha